Sleep · Austin area, TX
Sleep studies in Austin area, TX
16 recruiting studies have a site in the Austin area. This page includes nearby cities such as Round Rock, Cedar Park, Georgetown, Pflugerville.
16 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingHealthy volunteers
Safety and Effectiveness of Slow Wave Device for the Treatment of Obstructive Sleep Apnea
Slow Wave, Inc.
- Location
- Austin, TX
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol
Axsome Therapeutics, Inc.
- Location
- Austin, TX + 35 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 2/Phase 3
A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia
Alkermes, Inc.
- Location
- Austin, TX + 32 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 2
A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2)
Takeda
- Location
- Austin, TX + 24 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 3
A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight
Eli Lilly and Company
- Location
- Austin, TX + 22 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study Evaluating the Efficacy and Safety of Xywav Expanded Dosing vs Placebo in Participants With Narcolepsy or IH
Jazz Pharmaceuticals
- Location
- Austin, TX + 14 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1
Alkermes, Inc.
- Location
- Austin, TX + 21 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2
Alkermes, Inc.
- Location
- Austin, TX + 21 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 2/Phase 3
A Study to Investigate the Effects of Cleminorexton Compared With Placebo in the Treatment of Participants With Central Disorders of Hypersomnolence
Centessa Pharmaceuticals (UK) Limited
- Location
- Austin, TX + 19 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 2/Phase 3
A Study of TAK-360 in People With Narcolepsy or Idiopathic Hypersomnia
Takeda
- Location
- Austin, TX + 16 other US sites
- Eligibility basics
- Ages 18–71
- RecruitingPhase 3
A Phase 3 Efficacy and Safety Study of HBS-301 in Participants With Idiopathic Hypersomnia (IH)
Harmony Biosciences Management, Inc.
- Location
- Austin, TX + 39 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Phase 3 Efficacy and Safety Study of HBS-301 in Participants With Narcolepsy
Harmony Biosciences Management, Inc.
- Location
- Austin, TX + 26 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
A Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia
Centessa Pharmaceuticals (UK) Limited
- Location
- Austin, TX + 26 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 2
A Long-term Extension Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia
Centessa Pharmaceuticals (UK) Limited
- Location
- Austin, TX + 18 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingHealthy volunteers
Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
Duke University
- Location
- Austin, TX + 3 other US sites
- Eligibility basics
- Ages 0 mo–20
- RecruitingHealthy volunteers
Increased Dietary Protein Intake During GLP-1 Medication Use (in Middle-aged Women With Overweight/Obesity)
University of Texas at Austin
- Location
- Austin, TX
- Eligibility basics
- Ages 30–60 · Women only
Who these studies look for
Sleep studies often ask about shift work, caffeine and alcohol use, and medicines that affect sleep. Overnight lab studies usually require you to keep a set sleep schedule beforehand.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.